Distinct Profiles of Antibodies to Kaposi Sarcoma-Associated Herpesvirus Antigens in Patients with Kaposi Sarcoma, Multicentric Castleman Disease, and Primary Effusion Lymphoma
Distinct Profiles of Antibodies to Kaposi Sarcoma-Associated Herpesvirus Antigens in Patients with Kaposi Sarcoma, Multicentric Castleman Disease, and Primary Effusion Lymphoma
复制标题
DOI：
10.1086/652869
复制
发表时间：
2010-06-15
影响因子：
6.4
通讯作者：
Yarchoan, Robert
中科院分区：
文献类型：
--
作者：
Burbelo, Peter D.;Issa, Alexandra T.;Yarchoan, Robert
在卡波西肉瘤（KS）、多中心Castleman病（MCD）和原发性渗出性淋巴瘤患者中研究了针对溶解性和潜伏性卡波西肉瘤（KS）相关疱疹病毒抗原的抗体应答。MCD患者抗溶解性抗原K8.1的抗体是KS患者的5倍，而KS患者抗潜伏性抗原v-细胞周期蛋白和拉娜的抗体是MCD患者的27倍（P <0.001）。抗v-细胞周期蛋白和抗LANA抗体滴度的总和将KS患者与MCD和KS患者区分开来，敏感性为93%，特异性为83%。这些结果表明，抗体反应裂解和潜伏KS相关疱疹病毒抗原在这些疾病中不同。
Antibody responses against lytic and latent Kaposi sarcoma (KS)-associated herpesvirus antigens were investigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma. Antibodies against the lytic antigen K8.1 were 5-fold higher in patients with MCD than those with KS, whereas antibodies to the sum of latent antigens v-cyclin and LANA were 27-fold higher in patients with KS, compared with patients with MCD (P < .001). The sum of anti-v-cyclin and anti-LANA antibody titers discriminated patients with KS from those with MCD and KS with 93% sensitivity and 83% specificity. These results suggest that antibody responses to lytic and latent KS-associated herpesvirus antigens differ in these diseases.